Because persons with HCM who develop atrial fibrillation are at increased risk for thromboembolic complications, anticoagulation should be strongly considered in those with persistent or paroxysmal atrial fibrillation.

Affected individuals with obstructive physiology have traditionally been considered at moderate risk for infective endocarditis, and previous guidelines have recommended antibiotic prophylaxis for this subgroup. Official guidelines have been revised and decision making should be individualized [Wilson et al 2007].
